Neuronetics, Inc. (NASDAQ:STIM), a leader in interventional mental health that combines its NeuroSta

MALVERN, Pa., July 20, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interv

BTIG initiated coverage of Neuronetics Inc. (NASDAQ:STIM) on Monday, noting that the company is ente

BTIG initiates coverage on Neuronetics (STIM) with a Buy rating and $5 target as shares surge 28%. R

Gainers Zhengye Biotechnology (NASDAQ:ZYBT) shares increased by 322.6% to $2.95 during Monday's

BTIG analyst Sam Eiber initiates coverage on Neuronetics (NASDAQ:STIM) with a Buy rating and anno

Neuronetics is revisited following prior coverage in March 2026. The article focuses on STIM's recen

MALVERN, Pa., July 06, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interv

MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technolo

MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technolo

Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and

MALVERN, Pa., May 14, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technolog

Neuronetics, Inc. (STIM) Q1 2026 Earnings Call Transcript

Neuronetics (STIM) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Esti

Business OutlookFor the second quarter of 2026, the Company expects total revenue growth in the mid-

Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.16) per share which beat the analyst cons

MALVERN, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “N

MALVERN, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stag

MALVERN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a

Policy Update Broadens Access to Innovative, Non-Drug Depression Treatment Across 26 States and Wash

This week's deal activity spans gaming, healthcare, energy, and private equity, with activist sa

On April 2, 2026, the Company initiated a workforce reduction, which it expects to be completed by m

Neuronetics, Inc. (NASDAQ:STIM) (the "Company"), a medical technology company focused on des

MALVERN, Pa. , April 06, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the "Company"),

Delivers Letter to STIM Board Outlining Potential 5-7x Upside for Shareholders Inherent in Sale of T

Neuronetics, Inc. (NASDAQ: STIM - Get Free Report) major shareholder Jorey Chernett acquired 450,000

Canaccord Genuity analyst William Plovanic maintains Neuronetics (NASDAQ:STIM) with a Buy and low

Neuronetics, Inc. (STIM) Q4 2025 Earnings Call Transcript

Neuronetics (NASDAQ:STIM) sees FY2026 sales of $160.000 million-$166.000 million vs $164.167 million

Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.10) per share which beat the analyst cons

Total revenue of $41.8 million in Q4 2025, up 86% as reported and 23% on an adjusted pro forma basis

Seasoned leader brings more than 30 years of medical device experience, with a proven track record o

Neuronetics (NASDAQ: STIM - Get Free Report) and ADB International Group (OTCMKTS:EQUR - Get Free Re

  On Wednesday, 311 stocks hit new 52-week lows.

  On Tuesday, 647 companies set new 52-week lows.

  During the session on Thursday, 461 stocks hit new 52-week lows.

  During Thursday, 849 stocks hit new 52-week lows.

    On Friday, 209 companies set new 52-week lows.

Stocks That Hit 52-Week Lows On Wednesday

Stocks That Hit 52-Week Lows On Thursday

Stocks That Hit 52-Week Lows On Tuesday